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ABSTRACT
A simple, accurate and precise high performance thin layer chromatographic method has been 
developed for the estimation of Valsartan and Nebivolol hydrochloride simultaneously from a 
tablet dosage form. The method employed silica gel 60 F254 precoated plates as stationary phase 
and  a  mixture  of  Ethyl  acetate:  Methanol:  Ammonia  (6.5:2.5:0.5  %v/v/v)  as  mobile  phase. 
Densitometric scanning was performed at 280 nm using Camag TLC scanner 3. Beer’s law was 
obeyed in the concentration range of 800ng/spot-2400ng/spot for Nebivolol hydrochloride and 
200ng/spot-1000ng/spot for Valsartan. The Retention factors for Nebivolol hydrochloride is 0.75 
± 0.04 and for  Valsartan  is  0.27 ± 0.01.  The method was validated  as per ICH Guidelines, 
proving its utility in estimation of Valsartan and Nebivolol hydrochloride in combined dosage 
form.
Keywords:
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INTRODUCTION
Nebivolol hydrochloride is chemically known as{α, α’- [iminobis (methylene)] bis [6 fluoro- 3, 4 
– dihydro– 2H -1- benzopyran– methanol]} (1). Valsartan is chemically known as L-valine, N-
(1-oxopentyl)-N-[[2’-(1H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl.
Valsartan  is  angiostensin  II  blocker  and  is  used  as  an  antihypertensive  drug.  Nebivolol 
hydrochloride is selective β 1  adrenoreceptor antagonist, has vasodilating properties unrelated to 
β 2 stimulation or alpha blockade (2). Literature survey reveals that assay of Valsartan in bulk and 
dosage form is official in USP 2007 (3). Several analytical methods that have been reported for 
estimation of Valsartan and Nebivolol hydrochloride are HPLC (4-8), Spectrophotometric (9), 
thin layer chromatography (10-11) .The present paper describes a simple, accurate and precise 
method  for  simultaneous  estimation  of  Valsartan  and  Nebivolol  hydrochloride  in  combined 
tablet  dosage form. The proposed method is optimized and validated as per the International 
Conference on Harmonization (ICH) guidelines.
EXPERIMENTAL
Instruments:
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HPTLC system (Camag,  Muttenz, Switzerland)  comprising  of, Linomat  5  sample  applicator, 
twin-trough developing chamber and TLC Scanner 3 with WinCATS evaluation, ATS software 
(version 1.2.6) was used in the studies.
Reagents and Chemicals: 
Methanol  (AR grade)  was procured from Ashonuj specialties  Pvt.  Ltd.,  Mumbai.  AR Grade 
Ethyl acetate, Ammonia was procured from Loba chemie, Mumbai.
Working Standards:
Working  standards  of  Nebivolol  hydrochloride  was  procured  from Burgeon pharmaceuticals 
Pvt.Ltd, Pondicherry, India and Valsartan was procured from Lupin Research Park, Pune, India 
as a gift samples. Marketed formulation Nebicard-V (Nebivolol hydrochloride- 5 mg, Valsartan 
80 mg/tablet) was procured from local market.
PROCEDURE
Preparation of standard stock solution
25 mg of Valsartan and 25 mg of Nebivolol hydrochloride were weighed and transferred into 25 
ml volumetric flasks separately. To it 15ml methanol was added and shaken to dissolve the drug 
and volume was then made upto 25 ml so as to get the concentration 1mg/ml for both the drugs. 
Required amount of standard stock solution of both the drugs was diluted appropriately so as to 
get  the mixed standard solution containing  0.2mg/ml  Nebivolol  hydrochloride  and 0.1mg/ml 
Valsartan.  Each standard was applied as bands on TLC plates in five replicates.  Plates were 
developed  by  linear  ascending  development  using  neat  solvents  like  toluene,  methanol, 
chloroform, ethyl acetate, acetone, acetonitrile, etc. with chamber saturation. Based on the results 
of these initial  chromatograms binary and ternary mixtures of solvents were tried to achieve 
optimum resolution between Valsartan and Nebivolol hydrochloride respectively. After several 
trials,  mixture of Ethyl  acetate:  Methanol:  Ammonia (6.5: 2.5: 0.5 v/v/v)  was chosen as the 
mobile  phase for analysis.  The linearity  of the method was determined at  five concentration 
levels ranging from 200 to 1000 ng/spot for Valsartan and 800 to 2400 ng/spot for Nebivolol 
hydrochloride.    
Procedure for Analysis of Tablet Formulation
Twenty tablets were weighed accurately and powdered. Powder quantities equivalent to 5 mg of 
Nebivolol hydrochloride and 5 mg of Valsartan were weighed separately and transferred in two 
10 ml volumetric flasks. To each 5 ml of methanol was added and sonicated for 10 min. Volume 
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was then made upto 10 ml with methanol. Each solution was then filtered through whatman filter 
paper  No.41.  From  the  filtrate  of  both,  appropriate  volumes  were  spotted  to  obtain  final 
concentration of 400 ng/spot for Valsartan and 1200 ng/spot for Nebivolol hydrochloride. The 
peak  areas  of  the  spots  were  measured  at  280 nm and  concentrations  in  the  samples  were 
determined from the respective calibration curves. The amount of each drug present per tablet 
was calculated. The densitogram is shown in Fig 1.
               Figure 1: Densitogram of Nebivolol hydrochloride (1600ng/spot) and
                               Valsartan(600ng/spot)
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METHOD VALIDATION
As per the ICH guidelines, the method validation parameters checked were linearity & range, 
accuracy, precision, limit of detection, limit of quantitation and robustness.
Linearity and Range
Linearity of the method was checked using five different concentrations in the range of 200 to 
1000 ng/spot for Valsartan and 800 to 2400 ng/spot for Nebivolol hydrochloride. The linearity is 
indicated by regression equation. The Linear regression equations obtained are:  
For Nebivolol hydrochloride
For Valsartan                           
Accuracy and Precision
The accuracy of the method was determined by recovery experiments. The recovery studies were 
carried out at three levels of 80, 100 and 120% and the percentage recovery was calculated and 
presented in Table 1. Recovery was within the range of 100 ± 2% which indicates accuracy of 
the method.
Table-1 Results from recovery Studies
% Level Labelled
(mg/tab)
Amount added
(mg)
Amount 
recovered (mg)
% Recovery ±
S.D*
Valsartan
80 80 64 144.12 98.80 ±  0.168
100 80 80 159.83 99.98 ±  0.159
120 80 96 177.06 100.88 ±  0.233
Nebivolol hydrochloride
80 5 4 8.89 99.48 ±  1.112
100 5 5 10.09 100.12 ±  0.857
120 5 6 10.87 100.10 ±  0.170
*Standard deviation of three determinations
The precision of the method was demonstrated by inter day and intraday variation studies. In the 
intraday studies, three different concentrations of the mixed standard were analyzed in a day and 
percentage RSD were calculated and was found to be less than 1.5%. In the inter day variation 
studies,  three different  concentrations of the mixed standard were analyzed on 3 consecutive 
days and percentage RSD were calculated and was found to be less than 1.5%. The results of  
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interday  and  intraday  studies  are  shown  in  Table  2.  The  data  obtained  indicates  that  the 
developed HPTLC method is precise.
Table 2: Validation Parameters for Valsartan and Nebivolol hydrochloride
PARAMETERS VALSARTAN NEBIVOLOL 
HYDROCHLORIDE
Beer’s law range
(ng/spot)
200-1000 800-2400
Regression equation
y= mx + c
Slope (m)* 2.537 4.261
Intercept (c)* 162.27 -1552.80
% RSD (n=3)
Intraday precision
Interday precision
0.759
0.747
0.629
0.645
LODa 4.77 63.67
LOQb 14.46 192.94
LODa – Limit of detection
LOQb – Limit of Quantitation
* Average of five determination
Sensitivity
The  Limit  of  Detection  (LOD)  is  the  smallest  concentration  that  can  be  detected  but  not 
necessarily quantified as an exact value. LOD was calculated using the following formula  
                                                                 
The Limit of Quantification (LOQ) is the lowest amount of analyte in the sample that can be 
quantitatively determined with suitable precision and accuracy. LOQ was calculated using the 
following formula
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Robustness
The robustness of an analytical procedure is a measure of its capacity to remain unaffected by 
small  but  deliberate  variation  in  procedure.  Slight  and deliberate  changes  were  made to  the 
following parameters like changing the mobile phase ratio and chamber size, and the effect on 
the Rf values and peak areas were noted. In case of mobile phase ratio the % change in Rf Value 
was not  more than 0.08% & the % change in area was not more than 0.189 %. In case of 
Chamber change % change in Rf value was not more than 0.22% & the % change in area was not 
more than 0.117%. The method was found to be robust since the monitored parameters were not 
significantly affected.
Specificity
Specificity is the ability to access unequivocally the analyte in the presence of components that 
may be expected to be present such as impurities, degradation products.
It  is  done by spotting common excipients  during analysis  and it  was  found that  there is  no 
interference by excipients at the Rf value of the drug. 
Spectra of standard drug also match with the sample spectra and hence it is confirmed that the 
method is specific. The spectrum is shown in Fig 2.
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Figure 2: Spectra for Valsartan and Nebivolol hydrochloride
RESULTS AND DISCUSSIONS
As per the validation parameters checked, precision was indicated by % RSD value that is less 
than 1.5. Recovery of Valsartan on an average was 99.89% and for Nebivolol hydrochloride the 
value was 99.90%, indicating accuracy of the method. The details are shown in Table 2. The % 
assay values for Valsartan were found to be 100.13 ±  1.15% and for Nebivolol hydrochloride 
were found to be 100.49 ±  1.35%.
CONCLUSION
The  proposed  HPTLC  method  for  the  simultaneous  estimation  of  Valsartan  and  Nebivolol 
hydrochloride in combined dosage forms was found to be sensitive, accurate, precise, simple and 
rapid. Hence the present HPTLC method may be used for routine analysis of the raw materials  
and formulations.
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